Publications by authors named "Laurent Sebagh"
Coronary CT-Scan permits non-invasive visualization of all stages of coronary artery atherosclerosis allowing early therapeutic interventions, lifestyle changes and accurate follow-up all of which result in an improved prognosis. We discuss the possibility of a systematic coronary CT-scan in the global population at certain ages such as fifty or sixty years-old (or both). May this strategy decrease the onset of myocardial infarction or ischemic chronic heart failure thus improving quality (and quantity) of life? May it also reduce the medical costs for the individual and the society? Is it technically possible to deploy such a strategy? What would be the obstacles for its set up and what solutions might be proposed?
View Article and Find Full Text PDFObjectives: The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patient population.
Methods: Patient-level data from two all-comers observational studies (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled and analyzed in terms of their primary endpoint.
Article Synopsis
- The study evaluated the safety and effectiveness of ultrathin strut polymer-free sirolimus-eluting stents (PF-SES) in a diverse patient population undergoing percutaneous coronary interventions (PCI).
- A total of 7243 patients were included, showing a low target lesion revascularization (TLR) rate of 2.2% and a stent thrombosis rate of 0.7% over 9-12 months of follow-up.
- The results indicate that PF-SES are safe and effective, with particularly high procedural success rates in challenging cases like in-stent restenosis and isolated left main coronary artery disease.
Article Synopsis
- The study aimed to evaluate regional and ethnic differences in patients treated with polymer-free sirolimus-eluting stents (PF-SES) across Asia and Europe.
- It combined data from two observational studies, analyzing 7243 patients and focusing on target lesion revascularization (TLR) rates and major cardiovascular events (MACE) over 9-12 months.
- Results showed low TLR (2.2%) and MACE (4.4%) rates across regions, with notably longer dual antiplatelet therapy (DAPT) in Asia compared to Europe, indicating that longer DAPT may lead to even lower clinical event rates.
Aim: This open-label, randomized, and multicentre trial tested the hypothesis that, on a background of aspirin, continuing clopidogrel would be superior to stopping clopidogrel at 12 months following drug-eluting stent (DES) implantation.
Methods And Results: Patients (N = 1799) who had undergone placement of ≥1 DES for stable coronary artery disease or acute coronary syndrome were included in 58 French sites (January 2009-January 2013). Patients (N = 1385) free of major cardiovascular/cerebrovascular events or major bleeding and on aspirin and clopidogrel 12 months after stenting were eligible for randomization (1:1) between continuing clopidogrel 75 mg daily (extended-dual antiplatelet therapy, DAPT, group) or discontinuing clopidogrel (aspirin group).
Background: Dual antiplatelet therapy with aspirin and thienopyridine is required after placement of coronary drug-eluting stents (DES) to prevent thrombotic complications. Current clinical guidelines recommend at least 6 to 12 months of treatment after a DES implantation, but it may be beneficial to apply dual antiplatelet therapy for a longer duration.
Methods/design: The optimal dual antiplatelet therapy (OPTIDUAL) study aims to compare the benefits and risks of dual antiplatelet therapy applied for either 12 or 48 months.
Between January 1996 and May 2000, we retrospectively identified 66 patients (61 +/- 11 years) with in-stent restenosis who did not undergo percutaneous coronary intervention and/or bypass surgery and were maintained on medical treatment alone. In-stent restenosis was diffuse or proliferative in 86% of these patients. At 33 +/- 11 months, 2 patients died, none developed myocardial infarction, and 6 (9%) had target lesion revascularization only (repeat percutaneous transluminal coronary angioplasty).
View Article and Find Full Text PDFObjectives: This study was done to assess the results of percutaneous heart valve (PHV) implantation in non-surgical patients with end-stage calcific aortic stenosis.
Background: Replacement of PHV has been shown to be feasible in animals and humans. We developed a PHV composed of three pericardial leaflets inserted within a balloon-expandable stainless steel stent.